This Article  • Full text  • PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Surgery  • Biomaterials and Implants  • Cosmetic Surgery/ Procedures  • Alert me on articles by topic

David B. Apfelberg, MD; James Newman, MD; Miles Graivier, MD; Mark A. Petroff, MD; Richard Levine, MD

Arch Facial Plast Surg. 2008;10(4):280-282.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Since the introduction of the Endotine forehead fixation device (Coapt Systems, Palo Alto, California) in March 2003, there has been widespread acceptance of the product. The device has been implanted in over 40 000 patients, and its safety and efficacy have been documented by numerous multispecialty clinical studies.^1-7 Although the device has provided satisfactory elevation and fixation for endoscopic and open and coronal forehead-lifts, a small percentage of surgeons and patients have complained of problems related to persistent palpability and sensitivity owing to the 12- to 15-month absorption time of the biodegradable polymer.

The Ultratine forehead fixation device (Coapt) was cleared by the US Food and Drug Administration in 2006. It has the same dimensions as the original device, but the composition of the polymer has been altered to different percentages of polylactic acid . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION